Jordi Bruix

128.0k total citations · 42 hit papers
380 papers, 75.1k citations indexed

About

Jordi Bruix is a scholar working on Hepatology, Epidemiology and Oncology. According to data from OpenAlex, Jordi Bruix has authored 380 papers receiving a total of 75.1k indexed citations (citations by other indexed papers that have themselves been cited), including 312 papers in Hepatology, 185 papers in Epidemiology and 87 papers in Oncology. Recurrent topics in Jordi Bruix's work include Hepatocellular Carcinoma Treatment and Prognosis (266 papers), Liver Disease Diagnosis and Treatment (162 papers) and Liver Disease and Transplantation (74 papers). Jordi Bruix is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (266 papers), Liver Disease Diagnosis and Treatment (162 papers) and Liver Disease and Transplantation (74 papers). Jordi Bruix collaborates with scholars based in Spain, United States and Italy. Jordi Bruix's co-authors include Josep M. Llovet, Morris Sherman, Alejandro Forner, María Reig, Concepció Brú, Andrew K. Burroughs, Carmen Ayuso, Josep Fuster, Vincenzo Mazzaferro and María Sala and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jordi Bruix

372 papers receiving 73.8k citations

Hit Papers

Management of Hepatocellu... 1989 2026 2001 2013 2011 2005 2018 2012 2001 2.0k 4.0k 6.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Management of Hepatocellular Carcinoma: An Update Δσ
    2011 6.6k citations Jordi Bruix, Morris Sherman Hepatology profile →
  2. Management of Hepatocellular Carcinoma *
    2005 4.7k citations Jordi Bruix, Morris Sherman Hepatology profile →
  3. Hepatocellular carcinoma
    2018 4.1k citations Alejandro Forner, María Reig et al. profile →
  4. Hepatocellular carcinoma
    2012 3.4k citations Alejandro Forner, Josep M. Llovet et al. profile →
  5. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
    2001 3.4k citations Jordi Bruix, Morris Sherman et al. Journal of Hepatology profile →
  6. Hepatocellular carcinoma
    2003 3.1k citations Josep M. Llovet, Jordi Bruix et al. profile →
  7. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
    1999 3.0k citations Josep M. Llovet, Concepció Brú et al. profile →
  8. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
    2002 2.7k citations Josep M. Llovet, Xavier Montañá et al. profile →
  9. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    2003 2.4k citations Josep M. Llovet, Jordi Bruix Hepatology profile →
  10. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
    2021 2.3k citations María Reig, Alejandro Forner et al. Journal of Hepatology profile →
  11. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
    2008 1.3k citations Josep M. Llovet, Jordi Bruix et al. profile →
  12. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
    1999 1.3k citations Josep M. Llovet, Jordi Bruix et al. Hepatology profile →
  13. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
    2016 1.3k citations Jordi Bruix, María Reig et al. Gastroenterology profile →
  14. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
    2012 1.2k citations Josep M. Llovet, Tim F. Greten et al. profile →
  15. Hepatocellular carcinoma: clinical frontiers and perspectives
    2014 1.1k citations Jordi Bruix, Vincenzo Mazzaferro et al. profile →
  16. Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials
    1999 979 citations Josep M. Llovet, Antoni Castells et al. Hepatology profile →
  17. Prognostic prediction and treatment strategy in hepatocellular carcinoma
    2002 902 citations Jordi Bruix, Josep M. Llovet Hepatology profile →
  18. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
    2010 881 citations Alejandro Forner, María Reig et al. profile →
  19. Molecular targeted therapies in hepatocellular carcinoma†
    2008 836 citations Josep M. Llovet, Jordi Bruix Hepatology profile →
  20. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
    2015 771 citations Jordi Bruix, Vincenzo Mazzaferro et al. profile →
  21. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma
    2007 729 citations Alejandro Forner, R. Vilana et al. Hepatology profile →
  22. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
    2016 725 citations María Reig, Alba Díaz et al. Journal of Hepatology profile →
  23. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics
    2006 707 citations Marı́a Varela, Alejandro Forner et al. Journal of Hepatology profile →
  24. Novel advancements in the management of hepatocellular carcinoma in 2008
    2008 672 citations Josep M. Llovet, Jordi Bruix Journal of Hepatology profile →
  25. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
    2012 656 citations Jordi Bruix, Jean‐Luc Raoul et al. Journal of Hepatology profile →
  26. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure
    1996 653 citations Jordi Bruix, Antoni Castells et al. Gastroenterology profile →
  27. PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSIS
    1989 603 citations Jordi Bruix, Joan Rodés et al. profile →
  28. Increased Risk of Tumor Seeding After Percutaneous Radiofrequency Ablation for Single Hepatocellular Carcinoma
    2001 565 citations Josep M. Llovet, R. Vilana et al. Hepatology profile →
  29. Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†
    2007 559 citations Elisa Wurmbach, Ying‐Bei Chen et al. Hepatology profile →
  30. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma
    2004 535 citations Josep M. Llovet, Jordi Bruix et al. profile →
  31. Management of HCC
    2012 500 citations Carlos Rodríguez de Lope, Silvia Tremosini et al. Journal of Hepatology profile →
  32. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
    2016 479 citations Josep M. Llovet, María Reig et al. Journal of Hepatology profile →
  33. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
    2012 444 citations Josep M. Llovet, Gerold Meinhardt et al. Clinical Cancer Research profile →
  34. SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
    2014 438 citations Jordi Bruix, Josep M. Llovet et al. profile →
  35. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
    2017 421 citations Jordi Bruix, Ann‐Lii Cheng et al. Journal of Hepatology profile →
  36. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design
    2012 365 citations María Reig, Alejandro Forner et al. Journal of Hepatology profile →
  37. Treatment of intermediate-stage hepatocellular carcinoma
    2014 357 citations Alejandro Forner, Jordi Bruix et al. profile →
  38. LI‐RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI‐RADS Management Working Group and future directions
    2014 352 citations Jordi Bruix, Morris Sherman et al. Hepatology profile →
  39. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
    2017 334 citations Jordi Bruix et al. profile →
  40. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
    2018 262 citations Carmen Ayuso, Jordi Rimola et al. profile →
  41. Systemic treatment of hepatocellular carcinoma: An EASL position paper
    2021 243 citations Jordi Bruix, Peter R. Galle et al. Journal of Hepatology profile →
  42. Breakthroughs in Hepatocellular Carcinoma Therapies
    2023 82 citations Jordi Bruix et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jordi Bruix Spain 103 56.4k 34.0k 14.7k 12.7k 12.5k 380 75.1k
Josep M. Llovet Spain 116 55.9k 1.0× 31.2k 0.9× 15.5k 1.1× 17.2k 1.3× 19.1k 1.5× 357 85.2k
Masatoshi Kudo Japan 103 30.9k 0.5× 17.6k 0.5× 11.0k 0.7× 6.5k 0.5× 5.5k 0.4× 1.4k 48.7k
Vincenzo Mazzaferro Italy 74 26.0k 0.5× 15.9k 0.5× 10.8k 0.7× 6.2k 0.5× 6.5k 0.5× 364 39.1k
Gregory J. Gores United States 142 19.0k 0.3× 20.1k 0.6× 23.6k 1.6× 9.1k 0.7× 19.3k 1.5× 591 63.2k
Andrew X. Zhu United States 82 18.2k 0.3× 9.0k 0.3× 8.9k 0.6× 6.8k 0.5× 7.7k 0.6× 418 36.2k
Masatoshi Makuuchi Japan 97 28.1k 0.5× 13.2k 0.4× 25.3k 1.7× 4.4k 0.3× 4.3k 0.3× 782 48.1k
Richard S. Finn United States 76 15.9k 0.3× 8.1k 0.2× 3.6k 0.2× 8.3k 0.7× 9.0k 0.7× 370 38.2k
Morris Sherman Canada 58 24.1k 0.4× 17.2k 0.5× 5.3k 0.4× 4.5k 0.4× 4.5k 0.4× 203 31.8k
Peter Schirmacher Germany 86 10.6k 0.2× 9.2k 0.3× 6.8k 0.5× 7.6k 0.6× 10.9k 0.9× 681 36.7k
Riccardo Lencioni Italy 69 21.6k 0.4× 11.2k 0.3× 5.6k 0.4× 4.0k 0.3× 3.4k 0.3× 290 30.0k

Countries citing papers authored by Jordi Bruix

Since Specialization
Citations

This map shows the geographic impact of Jordi Bruix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordi Bruix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordi Bruix more than expected).

Fields of papers citing papers by Jordi Bruix

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordi Bruix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordi Bruix. The network helps show where Jordi Bruix may publish in the future.

Co-authorship network of co-authors of Jordi Bruix

This figure shows the co-authorship network connecting the top 25 collaborators of Jordi Bruix. A scholar is included among the top collaborators of Jordi Bruix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordi Bruix. Jordi Bruix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pérez-Saborido, B., Anna Darnell, Alejandro Forner, et al.. (2025). Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients. European Radiology. 35(9). 5771–5780. 1 indexed citations
2.
Forner, Alejandro, Jordi Rimola, Anna Darnell, et al.. (2022). Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR. Radiology and Oncology. 56(3). 292–302. 1 indexed citations
3.
Cucarull, Blanca, Anna Tutusaus, Milica Stefanović, et al.. (2020). Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers. 12(2). 332–332. 22 indexed citations
4.
Unfried, Juan P., Guillermo Serrano, Celia Prior, et al.. (2019). Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. Cancer Research. 79(20). 5167–5180. 28 indexed citations
5.
Huang, Liping, Yoriko De Sanctis, Minghua Shan, et al.. (2017). Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC). Annals of Oncology. 28. v239–v239. 1 indexed citations
6.
Yokosuka, Osamu, Gerold Meinhardt, & Jordi Bruix. (2017). Regorafenib as second-line treatment for patients with HCC who progressed on sorafenib: Japanese subgroup analysis of phase 3 RESORCE trial. 58. 65. 1 indexed citations
7.
Bruix, Jordi, María Reig, & Morris Sherman. (2016). Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 150(4). 835–853. 1259 indexed citations breakdown →
8.
Friesland, Martina, Mairene Coto‐Llerena, Sofía Pérez‐del‐Pulgar, et al.. (2014). Selective Inhibition of Hepatitis C Virus Infection by Hydroxyzine and Benztropine. Antimicrobial Agents and Chemotherapy. 58(6). 3451–3460. 21 indexed citations
9.
Toso, Christian, Vincenzo Mazzaferro, Jordi Bruix, et al.. (2014). Toward a Better Liver Graft Allocation That Accounts for Candidates With and Without Hepatocellular Carcinoma. American Journal of Transplantation. 14(10). 2221–2227. 44 indexed citations
10.
Lachenmayer, Anja, Clara Alsinet, Radoslav Savić, et al.. (2012). Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research. 18(18). 4997–5007. 230 indexed citations
11.
Raoul, Jean‐Luc, Jordi Bruix, Tim F. Greten, et al.. (2012). Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology. 56(5). 1080–1088. 102 indexed citations
12.
Villanueva, Augusto, Yujin Hoshida, Carlo Battiston, et al.. (2011). Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. Gastroenterology. 140(5). 1501–1512.e2. 312 indexed citations
13.
Tremosini, Silvia, Alejandro Forner, Loreto Boix, et al.. (2011). 1016 DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) ≤2 CM: PROSPECTIVE VALIDATION OF GLYPICAN 3, HEAT-SHOCK PROTEIN 70 AND GLUTAMINE SYNTHETASE S TAINING IN BIOPSY SAMPLES. Journal of Hepatology. 54. S404–S404. 1 indexed citations
14.
Toffanin, Sara, Yujin Hoshida, Anja Lachenmayer, et al.. (2011). MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology. 140(5). 1618–1628.e16. 171 indexed citations
15.
Reig, María, Alejandro Forner, Jordi Rimola, et al.. (2009). 815 SORAFENIB FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA. FEASIBILITY AND SAFETY OUTSIDE RESEARCH TRIALS. Journal of Hepatology. 50. S298–S298. 1 indexed citations
16.
Galle, Peter R., Jean‐Frédéric Blanc, Jean‐Luc Van Laethem, et al.. (2008). 994 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND PRIOR ANTI-TUMOR THERAPY: A SUBANALYSIS FROM THE SHARP TRIAL. Journal of Hepatology. 48. S372–S372. 10 indexed citations
17.
Wurmbach, Elisa, Ying‐Bei Chen, Greg Khitrov, et al.. (2007). Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma†. Hepatology. 45(4). 938–947. 559 indexed citations breakdown →
18.
Forner, Alejandro, Marı́a Varela, L Bianchi, & Jordi Bruix. (2006). Detección precoz del carcinoma hepatocelular en pacientes cirróticos. Gastroenterología y Hepatología. 29(1). 5–8.
19.
Bruix, Jordi, Loreto Boix, María Sala, & Josep M. Llovet. (2004). Focus on hepatocellular carcinoma. Cancer Cell. 5(3). 215–219. 480 indexed citations
20.
Bruix, Jordi, Josep M. Llovet, Antoni Castells, et al.. (1998). Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology. 27(6). 1578–1583. 418 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Josep M. Llovet Breakdown of academic impact, for papers by Masatoshi Kudo Breakdown of academic impact, for papers by Vincenzo Mazzaferro Breakdown of academic impact, for papers by Gregory J. Gores Breakdown of academic impact, for papers by Andrew X. Zhu Breakdown of academic impact, for papers by Masatoshi Makuuchi Breakdown of academic impact, for papers by Richard S. Finn Breakdown of academic impact, for papers by Morris Sherman Breakdown of academic impact, for papers by Peter Schirmacher Breakdown of academic impact, for papers by Riccardo Lencioni
Rankless by CCL
2026